In 1992 Dr. Wilfred Jefferies, discovered that the human protein p97 was associated with Alzheimer's Disease. This discovery suggested the possibility that p97 could be used as a "biomarker" for Alzheimer's and might be useful in the early detection and diagnosis of this heretofore difficult to diagnose disease.
Two triple blind validation studies have confirmed that p97 is a biomarker for Alzheimer's Disease.
In December 2008, A SISCAPA assay for p97 was developed for biOasis by the Anderson Forchung Group of Washington DC. demonstrating the ability to reliably detect p97 in plasma and assisting biOasis in developing this unique and valuable diagnostic test for Alzheimer's.
Fleet Bioprocessing of London England is in now the final stages in the development of CogniTEST as a rapid blood test serum that can test and differentiate between Alzheimer's and non-Alzheimer's dementia in humans.
Human Clinical Sample testing begins - June 2011 through October 2011 and a CE Mark Application for Europe will be applied for thereafter. It is expected that CogniTEST will be ready for out-source licensing by the fourth quarter of 2011.
|
|
TRANSCEND is a protein Vector to shuttle existing therapeutic drugs across the Blood-Brain Barrier.
In November 2010 Bioasis sponsored a research agreement with the National Research Council of Canada to evaluate the ability of biOasis' compounds to cross the blood-brain barrier using real time-domain in vivo optical imaging.
Prior research studies have revealed that Transcend could be conjugated with therapeutic molecules to act as a shuttle that could essentially piggy-back drugs across the Blood-Brian Barrier to deliver these therapies into the cellular level of the brain. This would represent a major break through in the treatment of Central Nervous System diseases that has heretofore been hampered by the inability to deliver drug therapies through the Blood Brain Barrier and "into the parenchyma" ~ into the cellular level of the brain.
In January 2011, the National Research Council confirmed through a fluorescence imaging study that Transcend can shuttle compounds across the blood-brain barrier. View florescence imaging slides.
|